PharmaCyte Biotech Boosts Stake in TNF Pharmaceuticals Amid Groundbreaking Computing Platform Partnership

PharmaCyte Biotech has increased its stake in TNF Pharmaceuticals by $3 million to support TNF's license acquisition of LightSolver's processing accelerator. This technology reduces energy usage by 90% and is set to revolutionize cryptocurrency mining and blockchain operations. PharmaCyte Biotech remains well-capitalized with over $55 million in total assets.

TNF Pharmaceuticals has secured exclusive global rights to an innovative light-based computing accelerator developed by LightSolver Ltd., marking a significant shift in its strategic trajectory. The acquisition, supported by a $3 million increase in stake by PharmaCyte Biotech, positions TNF at the forefront of a technological revolution in cryptocurrency computing.

LightSolver's Laser Processing Unit (LPU) harnesses light for computation, offering an accelerated method that can solve complex problems at the speed of light. This technology is set to reduce energy costs by up to 90% in cryptocurrency applications, potentially transforming the industry's sustainability. The partnership between TNF and LightSolver is supported by a strategic investment from TNF's largest stockholder, enabling the company to pursue a name change to reflect its new direction. TNF plans to leverage this technology to develop a scalable solution for cryptocurrency infrastructure, aiming to reduce energy consumption and enhance computational efficiency [1].

TNF Pharmaceuticals has also entered into a $7.0 million private placement financing agreement, involving the sale of 7,000 shares of its Series H convertible preferred stock. This funding will support the commercialization and development strategy for the licensed technology. LightSolver, a 2025 World Economic Forum Technology Pioneer, has drawn significant attention for its breakthrough innovation. The company's technology has been recognized by Gartner as a sample vendor in the 2025 Hype Cycle for Data Center Infrastructure Technologies [1].

PharmaCyte Biotech, a well-capitalized entity with over $55 million in total assets, has increased its stake in TNF Pharmaceuticals by $3 million to support the license acquisition of LightSolver's processing accelerator. This technology is poised to revolutionize cryptocurrency mining and blockchain operations, offering substantial energy savings and computational efficiency.

TNF Pharmaceuticals is positioned to capitalize on the growing momentum behind photonic computing and the future of cryptocurrency infrastructure. The company believes it holds first-mover advantages in this burgeoning industry, setting it up for growth and value creation [1].

References:
[1] https://www.morningstar.com/news/business-wire/20250902945912/tnf-pharmaceuticals-secures-exclusive-global-rights-to-innovative-light-speed-computing-accelerator-for-use-in-cryptocurrency-applications